Literature DB >> 3872661

Comparison of the biological properties of purified natural and recombinant human interleukin-2.

K Naruo, S Hinuma, K Kato, M Koyama, H Tada, O Shiho, K Tsukamoto.   

Abstract

We compared the biological properties of the purified recombinant human IL-2 derived from E. coli with those of purified natural IL-2. Both had almost the same specific in vitro activities on a weight basis to support long-term proliferation of IL-2 dependent human peripheral blood lymphocytes, a mouse killer T cell line, and a mouse natural killer cell line; induce killer cells in normal mouse spleen cells; and induce antibody forming cells in nude mouse spleen cells. No differences in these biological activities were found between two forms of natural IL-2 that were separable by reverse phase high performance liquid chromatography.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872661     DOI: 10.1016/0006-291x(85)91672-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients.

Authors:  H Shiratsuchi; Y Okuda; I Tsuyuguchi
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

3.  Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization.

Authors:  H Yagura; T Tamaki; T Furitsu; Y Tomiyama; T Nishiura; N Tominaga; S Katagiri; T Yonezawa; S Tarui
Journal:  Blut       Date:  1990-03

4.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Interleukin 2 receptor bearing T lymphocytes in patients with chronic liver disease.

Authors:  S Kakumu; K Yoshioka; A Fuji; H Tahara
Journal:  Gastroenterol Jpn       Date:  1988-08

6.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

7.  Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

Authors:  S Hinuma; K Naruo; K Ootsu; T Houkan; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.

Authors:  S Hinuma; K Naruo; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

9.  Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.

Authors:  H Uchida; K Taniguchi; K Nomoto
Journal:  Jpn J Cancer Res       Date:  1990-04

10.  Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1989-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.